Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600658 | 0.81 | MAPK14 (0.43) | GRM4JAK3LCKMAPK14MAPK9 | |
| SCHEMBL599751 | 0.79 | LMNA (0.42) | LMNAKMT2AJAK3CYP3A4ALDH1A1 | |
| SCHEMBL2946490 | 0.75 | MTOR (0.43) | LMNAKMT2AJAK3CYP3A4ALDH1A1 | |
| SCHEMBL2946488 | 0.75 | MTOR (0.43) | LMNAKMT2AJAK3CYP3A4ALDH1A1 | |
| SCHEMBL2948210 | 0.75 | JAK3 (0.43) | GRM4LMNAKMT2AJAK3CYP3A4 | |
| SCHEMBL2948212 | 0.75 | JAK3 (0.43) | GRM4LMNAKMT2AJAK3CYP3A4 | |
| SCHEMBL600573 | 0.74 | LMNA (0.53) | LMNAKMT2ALCKALDH1A1MAPT | |
| SCHEMBL11987723 | 0.67 | LMNA (0.36) | LMNAKMT2AJAK3CYP3A4ALDH1A1 | |
| SCHEMBL601354 | 0.65 | MAPK14 (0.47) | LMNAKMT2ALCKCYP3A4ALDH1A1 | |
| SCHEMBL28462412 | 0.64 | SYK (0.39) | LMNACYP3A4ALDH1A1MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | claimed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | claimed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | claimed |
| US-8497269-B2 | Phthalazine compounds as p38 map kinase modulators and methods of use thereof | AMGEN INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | AMGEN INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2010042649-A2 | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040983-A1 | Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof | MAPK1, MAPK4, MAPK12 | GRM4 925/4885LMNA 4011/4885KMT2A 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.